Patents by Inventor Timothy D. Connors

Timothy D. Connors has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200317761
    Abstract: Provided herein multispecific (e.g., bispecific) binding molecules comprising a first binding domain that binds an extracellular portion of dystroglycan and a second binding domain that binds laminin-2. Further provided herein are methods for making such binding molecules and uses of such binding molecules for treating and/or preventing alpha-dystroglycanopathies.
    Type: Application
    Filed: March 13, 2020
    Publication date: October 8, 2020
    Inventors: Christian BEIL, William H. BRONDYK, Yangde CHEN, Seng H. CHENG, Timothy D. CONNORS, Catherine DEVAUD, Dietmar HOFFMANN, Christian LANGE, Maureen MAGNAY, Tristan MAGNAY, Catherine PRADES, Ercole RAO, Leila SEVIGNY, Ronnie WEI, Hongmei ZHAO, Yunxiang ZHU
  • Patent number: 10626169
    Abstract: Provided herein multispecific (e.g., bispecific) binding molecules comprising a first binding domain that binds an extracellular portion of dystroglycan and a second binding domain that binds laminin-2. Further provided herein are methods for making such binding molecules and uses of such binding molecules for treating and/or preventing alpha-dystroglycanopathies.
    Type: Grant
    Filed: February 16, 2018
    Date of Patent: April 21, 2020
    Assignee: Sanofi
    Inventors: Christian Beil, William H. Brondyk, Yangde Chen, Seng H. Cheng, Timothy D. Connors, Catherine Devaud, Dietmar Hoffmann, Christian Lange, Maureen Magnay, Tristan Magnay, Catherine Prades, Ercole Rao, Leila Sevigny, Ronnie Wei, Hongmei Zhao, Yunxiang Zhu
  • Publication number: 20190119391
    Abstract: The present disclosure provides anti-CXCR3 antibodies and methods of using the antibodies to diagnose and/or treat CXCR3-associated disorders such as diabetes mellitus type I (T1D), particularly new-onset T1D. In certain embodiments, disclosed herein are CXCR3 neutralizing antibodies.
    Type: Application
    Filed: September 14, 2018
    Publication date: April 25, 2019
    Inventors: Michele Youd, Jennifer Tedstone, Tracey Lodie, Karen B. Carter, Timothy D. Connors, Jason Robert Pinckney, Elizabeth Masterjohn, Ruiyin Chu
  • Publication number: 20180244787
    Abstract: Provided are methods and uses of anti-CXCR3 antibodies to treat CXCR3-associated disorders such as vitiligo. In certain embodiments, the anti-CXCR3 antibodies are humanized anti-human CXCR3 antibodies with enhanced effector function against cells expressing CXCR3 on their surface.
    Type: Application
    Filed: December 21, 2017
    Publication date: August 30, 2018
    Inventors: William H. Brondyk, Ruiyin Chu, Timothy D. Connors, Sunghae Park, Huawei Qiu, Michele Youd, John Harris, Jillian Richmond
  • Publication number: 20180237511
    Abstract: Provided herein multispecific (e.g., bispecific) binding molecules comprising a first binding domain that binds an extracellular portion of dystroglycan and a second binding domain that binds laminin-2. Further provided herein are methods for making such binding molecules and uses of such binding molecules for treating and/or preventing alpha-dystroglycanopathies.
    Type: Application
    Filed: February 16, 2018
    Publication date: August 23, 2018
    Inventors: Christian Beil, William H. Brondyk, Yangde Chen, Seng H. Cheng, Timothy D. Connors, Catherine Devaud, Dietmar Hoffmann, Christian Lange, Maureen Magnay, Tristan Magnay, Catherine Prades, Ercole Rao, Leila Sevigny, Ronnie Wei, Hongmei Zhao, Yunxiang Zhu
  • Publication number: 20180214542
    Abstract: Provided are humanized CXCR3 antibodies and methods of using the antibodies to treat CXCR3-associated disorders such as type 1 diabetes mellitus (T1D), particularly new-onset T1D, and psoriasis. In certain embodiments, the anti-CXCR3 antibodies are humanized anti-human CXCR3 antibodies with enhanced effector function against cells expressing CXCR3 on their surface. Also provided are nucleic acid sequences encoding the antibodies, and pharmaceutical compositions comprising the antibodies.
    Type: Application
    Filed: December 21, 2017
    Publication date: August 2, 2018
    Inventors: William H. Brondyk, Ruiyin Chu, Timothy D. Connors, Sunghae Park, Huawei Qiu, Michele Youd
  • Publication number: 20180086838
    Abstract: The present disclosure provides anti-CXCR3 antibodies and methods of using the antibodies to diagnose and/or treat CXCR3-associated disorders such as diabetes mellitus type I (T1D), particularly new-onset T1D. In certain embodiments, disclosed herein are CXCR3 neutralizing antibodies.
    Type: Application
    Filed: August 4, 2017
    Publication date: March 29, 2018
    Inventors: Michele Youd, Jennifer Tedstone, Tracey Lodie, Karen B. Carter, Timothy D. Connors, Jason Robert Pinckney, Elizabeth Masterjohn, Ruiyin Chu
  • Patent number: 9765144
    Abstract: The present disclosure provides anti-CXCR3 antibodies and methods of using the antibodies to diagnose and/or treat CXCR3-associated disorders such as diabetes mellitus type I (T1D), particularly new-onset T1D. In certain embodiments, disclosed herein are CXCR3 neutralizing antibodies.
    Type: Grant
    Filed: September 8, 2014
    Date of Patent: September 19, 2017
    Assignee: GENZYME CORPORATION
    Inventors: Michele Youd, Jennifer Tedstone, Tracey Lodie, Karen B. Carter, Timothy D. Connors, Jason Robert Pinckney, Elizabeth Masterjohn, Ruiyin Chu
  • Publication number: 20140377806
    Abstract: The present disclosure provides anti-CXCR3 antibodies and methods of using the antibodies to diagnose and/or treat CXCR3-associated disorders such as diabetes mellitus type I (T1D), particularly new-onset T1D. In certain embodiments, disclosed herein are CXCR3 neutralizing antibodies.
    Type: Application
    Filed: September 8, 2014
    Publication date: December 25, 2014
    Inventors: Michele Youd, Jennifer Tedstone, Tracey Lodie, Karen B. Carter, Timothy D. Connors, Jason Robert Pinckney, Elizabeth Masterjohn, Ruiyin Chu
  • Patent number: 8865870
    Abstract: The present disclosure provides anti-CXCR3 antibodies and methods of using the antibodies to diagnose and/or treat CXCR3-associated disorders such as diabetes mellitus type I (T1D), particularly new-onset T1D. In certain embodiments, disclosed herein are CXCR3 neutralizing antibodies.
    Type: Grant
    Filed: January 18, 2013
    Date of Patent: October 21, 2014
    Assignee: Genzyme Corporation
    Inventors: Michele Youd, Jennifer Tedstone, Tracey Lodie, Karen B. Carter, Timothy D. Connors, Jason Robert Pinckney, Elizabeth Masterjohn, Ruiyin Chu
  • Publication number: 20130251733
    Abstract: The present disclosure provides anti-CXCR3 antibodies and methods of using the antibodies to diagnose and/or treat CXCR3-associated disorders such as diabetes mellitus type I (T1D), particularly new-onset T1D. In certain embodiments, disclosed herein are CXCR3 neutralizing antibodies.
    Type: Application
    Filed: January 18, 2013
    Publication date: September 26, 2013
    Applicant: Genzyme Corporation
    Inventors: Michele Youd, Jennifer Tedstone, Tracey Lodie, Karen B. Carter, Timothy D. Connors, Jason Robert Pinckney, Elizabeth Masterjohn, Ruiyin Chu
  • Patent number: 6972176
    Abstract: The genomic structure including the sequence of the intron/exon junctions is disclosed for KVLQT1 and KCNE1 which are genes associated with long QT syndrome. Additional sequence data for the two genes ARE also disclosed. Also disclosed are newly found mutations in KVLQT1 which result in long QT syndrome. The intron/exon junction sequence data allow for the design of primer pairs to amplify and sequence across all of the exons of the two genes. This can be used to screen persons for the presence of mutations which cause long QT syndrome. Assays can be performed to screen persons for the presence of mutations in either the DNA or proteins. The DNA and proteins may also be used in assays to screen for drugs which will be useful in treating or preventing the occurrence of long QT syndrome.
    Type: Grant
    Filed: February 20, 2003
    Date of Patent: December 6, 2005
    Assignees: University of Utah Research Foundation, Genzyme Corporation
    Inventors: Mark T. Keating, Michael C. Sanguinetti, Mark E. Curran, Gregory M. Landes, Timothy D. Connors, Timothy C. Burn, Igor Splawski, Qing Wang
  • Patent number: 6867288
    Abstract: The present invention provides methods and compositions for treating cyst formation in PKD1-associated epithelial cells. Such methods encompass administering an isolated human PKD1 gene, or fragments of the gene, under conditions that result in expression of therapeutically effective amounts of all, or part of, the PKD1 protein. The invention also encompasses compositions for treating cyst formation associated with APKD.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: March 15, 2005
    Assignees: Genzyme Corporation, Johns Hopkins University
    Inventors: Katherine W. Klinger, Gregory M. Landes, Timothy C. Burn, Timothy D. Connors, William Dackowski, Gregory Germino, Feng Qian
  • Publication number: 20030170708
    Abstract: The genomic structure including the sequence of the intron/exon junctions is disclosed for KVLQT1 and KCNE1 which are genes associated with long QT syndrome. Additional sequence data for the two genes ARE also disclosed. Also disclosed are newly found mutations in KVLQT1 which result in long QT syndrome. The intron/exon junction sequence data allow for the design of primer pairs to amplify and sequence across all of the exons of the two genes. This can be used to screen persons for the presence of mutations which cause long QT syndrome. Assays can be performed to screen persons for the presence of mutations in either the DNA or proteins. The DNA and proteins may also be used in assays to screen for drugs which will be useful in treating or preventing the occurrence of long QT syndrome.
    Type: Application
    Filed: February 20, 2003
    Publication date: September 11, 2003
    Inventors: Mark T. Keating, Michael C. Sanguinetti, Mark E. Curran, Gregory M. Landes, Timothy D. Connors, Timothy C. Burn, Igor Splawski
  • Patent number: 6582913
    Abstract: The genomic structure including the sequence of the intron/exon junctions is disclosed for KVLQT1 and KCNE1 which are genes associated with long QT syndrome. Additional sequence data for the two genes ARE also disclosed. Also disclosed are newly found mutations in KVLQT1 which result in long QT syndrome. The intron/exon junction sequence data allow for the design of primer pairs to amplify and sequence across all of the exons of the two genes. This can be used to screen persons for the presence of mutations which cause long QT syndrome. Assays can be performed to screen persons for the presence of mutations in either the DNA or proteins. The DNA and proteins may also be used in assays to screen for drugs which will be useful in treating or preventing the occurrence of long QT syndrome.
    Type: Grant
    Filed: June 19, 2000
    Date of Patent: June 24, 2003
    Assignees: University of Utah Research Foundation, Genzyme, Inc.
    Inventors: Mark T. Keating, Michael C. Sanguinetti, Mark E. Curran, Gregory M. Landes, Timothy D. Connors, Timothy C. Burn, Igor Splawski
  • Patent number: 6451534
    Abstract: The genomic structure including the sequence of the intron/exon junctions is disclosed for KVLQT1 and KCNE1 which are genes associated with long QT syndrome. Additional sequence data for the two genes ARE also disclosed. Also disclosed are newly found mutations in KVLQT1 which result in long QT syndrome. The intron/exon junction sequence data allow for the design of primer pairs to amplify and sequence across all of the exons of the two genes. This can be used to screen persons for the presence of mutations which cause long QT syndrome. Assays can be performed to screen persons for the presence of mutations in either the DNA or proteins. The DNA and proteins may also be used in assays to screen for drugs which will be useful in treating or preventing the occurrence of long QT syndrome.
    Type: Grant
    Filed: June 19, 2000
    Date of Patent: September 17, 2002
    Assignees: University of Utah Research Foundation, Genzyme Corporation
    Inventors: Mark T. Keating, Michael C. Sanguinetti, Mark E. Curran, Gregory M. Landes, Timothy D. Connors, Timothy C. Burn, Igor Splawski
  • Patent number: 6420124
    Abstract: The genomic structure including the sequence of the intron/exon junctions is disclosed for KVLQT1 and KCNE1 which are genes associated with long QT syndrome. Additional sequence data for the two genes ARE also disclosed. Also disclosed are newly found mutations in KVLQT1 which result in long QT syndrome. The intron/exon junction sequence data allow for the design of primer pairs to amplify and sequence across all of the exons of the two genes. This can be used to screen persons for the presence of mutations which cause long QT syndrome. Assays can be performed to screen persons for the presence of mutations in either the DNA or proteins. The DNA and proteins may also be used in assays to screen for drugs which will be useful in treating or preventing the occurrence of long QT syndrome.
    Type: Grant
    Filed: June 19, 2000
    Date of Patent: July 16, 2002
    Assignees: University of Utah Research Foundation, Genzyme Corporation
    Inventors: Mark T. Keating, Michael C. Sanguinetti, Mark E. Curran, Gregory M. Landes, Timothy D. Connors, Timothy C. Burn, Igor Splawski
  • Patent number: 6277978
    Abstract: The genomic structure including the sequence of the intron/exon junctions is disclosed for KVLQT1 and KCNE1 which are genes associated with long QT syndrome. Additional sequence data for the two genes are also disclosed. Also disclosed are newly found mutations in KVLQT1 which result in long QT syndrome. The intron/exon junction sequence data allow for the design of primer pairs to amplify and sequence across all of the exons of the two genes. This can be used to screen persons for the presence of mutations which cause long QT syndrome. Assays can be performed to screen persons for the presence of mutations in either the DNA or proteins. The DNA and proteins may also be used in assays to screen for drugs which will be useful in treating or preventing the occurrence of long QT syndrome.
    Type: Grant
    Filed: August 17, 1998
    Date of Patent: August 21, 2001
    Assignees: University of Utah Research Foundation, Genzyme Corporation
    Inventors: Mark T. Keating, Michael C. Sanguinetti, Mark E. Curran, Gregory M. Landes, Timothy D. Connors, Timothy C. Burn, Igor Splawski
  • Patent number: 6030806
    Abstract: In accordance with the present invention, there are provided isolated nucleic acids encoding a human netrin, a human ATP binding cassette transporter, a human ribosomal L3 subtype, and a human augmenter of liver regeneration as well as isolated protein products encoded thereby. The present invention provides nucleic acid probes that hybridize to invention nucleic acids as well as isolated nucleic acids comprising unique gene sequences located on chromosome 16. Further provided are vectors containing invention nucleic acids, host cells transformed therewith, as well as transgenic non-human mammals that express invention polypeptides. The present invention includes antisense oligonucleotides, antibodies and compositions containing same. Additionally, the invention provides methods for identifying compounds that bind to invention polypeptides.
    Type: Grant
    Filed: December 9, 1996
    Date of Patent: February 29, 2000
    Inventors: Gregory M. Landes, Timothy C. Burn, Timothy D. Connors, William R. Dackowski, Terence J. Van Raay, Katherine W. Klinger
  • Patent number: 5654170
    Abstract: The present invention involves isolated nucleic acid encoding human PKD1, and sequences derived therefrom. The invention also encompasses vectors comprising these nucleic acids, host cells transformed with the vectors, and methods for producing PKD1 protein or fragments thereof. In another aspect, the invention involves isolated oligonucleotides that hybridize only to the authentic expressed PKD1 gene, and not to PKD1 homologues. In yet another aspect, the invention involves isolated mutant PKD1 genes, and their cDNA cognates. Further provided are isolated oligonucleotides that discriminate between normal and mutant versions of the PKD1 gene. Methods and compositions for treating APKD or disease conditions having the characteristics of APKD are also provided.
    Type: Grant
    Filed: October 12, 1994
    Date of Patent: August 5, 1997
    Assignees: Johns Hopkins University, Genzyme Corporation
    Inventors: Katherine W. Klinger, Gregory M. Landes, Timothy C. Burn, Timothy D. Connors, William Dackowski, Gregory Germino, Feng Qian